Skip to main content
Top
Published in: Clinical Drug Investigation 7/2015

Open Access 01-07-2015 | Original Research Article

A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers

Authors: Ramesh Boinpally, Laishun Chen, Stephen R. Zukin, Natalie McClure, Robert K. Hofbauer, Antonia Periclou

Published in: Clinical Drug Investigation | Issue 7/2015

Login to get access

Abstract

Background

Combining two standard-of-care medications for Alzheimer’s disease (AD) into a single once-daily dosage unit may improve treatment adherence, facilitate drug administration, and reduce caregiver burden. A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil was evaluated for bioequivalence with co-administered commercially available memantine ER and donepezil, and for bioavailability with regard to food intake.

Methods

Two phase I, single-dose, randomized, open-label, crossover studies were conducted in 18- to 45-year-old healthy individuals. In MDX-PK-104 study, fasting participants (N = 38) received co-administered memantine ER and donepezil or the FDC. In MDX-PK-105 study, participants (N = 36) received three treatments: intact FDC taken while fasting or after a high-fat meal, or FDC contents sprinkled on applesauce while fasting. Standard pharmacokinetic parameters for memantine and donepezil were calculated from the plasma concentration time-curve using non-compartmental analyses. Linear mixed-effects models were used to compare: (a) FDC versus co-administered individual drugs; (b) FDC fasted versus with food; and (c) FDC sprinkled on applesauce versus FDC intact, both fasted. Safety parameters were also evaluated.

Results

The FDC capsule was bioequivalent to co-administered memantine ER and donepezil. There was no significant food effect on the bioavailability of the FDC components. There were no clinically relevant differences in time to maximum plasma concentration or safety profiles across treatments.

Conclusions

An FDC capsule containing 28 mg memantine ER and 10 mg donepezil is bioequivalent to commercially available memantine ER and donepezil, and bioavailability is not affected by food intake or sprinkling of capsule contents on applesauce.
Literature
1.
go back to reference Callahan CM, Sachs GA, Lamantia MA, Unroe KT, Arling G, Boustani MA. Redesigning systems of care for older adults with Alzheimer’s disease. Health Aff. 2014;33(4):626–32.CrossRef Callahan CM, Sachs GA, Lamantia MA, Unroe KT, Arling G, Boustani MA. Redesigning systems of care for older adults with Alzheimer’s disease. Health Aff. 2014;33(4):626–32.CrossRef
2.
go back to reference Farrell B, French Merkley V, Ingar N. Reducing pill burden and helping with medication awareness to improve adherence. Can Pharm J. 2013;146(5):262–9.CrossRef Farrell B, French Merkley V, Ingar N. Reducing pill burden and helping with medication awareness to improve adherence. Can Pharm J. 2013;146(5):262–9.CrossRef
3.
go back to reference Prohaska TR, Anderson LA, Binstock RH. Public health for an aging society. Baltimore: Johns Hopkins University Press; 2012. Prohaska TR, Anderson LA, Binstock RH. Public health for an aging society. Baltimore: Johns Hopkins University Press; 2012.
4.
go back to reference Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer’s disease patients receiving oral therapy. Curr Med Res Opin. 2010;26(8):1957–65.PubMedCrossRef Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer’s disease patients receiving oral therapy. Curr Med Res Opin. 2010;26(8):1957–65.PubMedCrossRef
5.
go back to reference Humbert IA, McLaren DG, Kosmatka K, Fitzgerald M, Johnson S, Porcaro E, et al. Early deficits in cortical control of swallowing in Alzheimer’s disease. J Alzheimer’s Dis. 2010;19(4):1185–97. Humbert IA, McLaren DG, Kosmatka K, Fitzgerald M, Johnson S, Porcaro E, et al. Early deficits in cortical control of swallowing in Alzheimer’s disease. J Alzheimer’s Dis. 2010;19(4):1185–97.
6.
go back to reference Molinuevo JL, Arranz FJ. Assessment of the strategies to improve therapeutic compliance in routine clinical practice in noncompliant patients with Alzheimer-type dementia. Rev Neurologia. 2012;54(2):65–73. Molinuevo JL, Arranz FJ. Assessment of the strategies to improve therapeutic compliance in routine clinical practice in noncompliant patients with Alzheimer-type dementia. Rev Neurologia. 2012;54(2):65–73.
7.
go back to reference Tjia J, Rothman MR, Kiely DK, Shaffer ML, Holmes HM, Sachs GA, et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc. 2010;58(5):880–8.PubMedCentralPubMedCrossRef Tjia J, Rothman MR, Kiely DK, Shaffer ML, Holmes HM, Sachs GA, et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc. 2010;58(5):880–8.PubMedCentralPubMedCrossRef
8.
go back to reference McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006(2):CD003154. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006(2):CD003154.
9.
go back to reference Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006(1):CD005593. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006(1):CD005593.
10.
go back to reference Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.PubMedCrossRef Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.PubMedCrossRef
11.
go back to reference Grossberg GT, Manes F, Allegri RF, Gutierrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469–78.PubMedCentralPubMedCrossRef Grossberg GT, Manes F, Allegri RF, Gutierrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469–78.PubMedCentralPubMedCrossRef
12.
go back to reference Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol. 2013;69(7):1467–75.PubMedCrossRef Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol. 2013;69(7):1467–75.PubMedCrossRef
13.
go back to reference Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psych. 2011;168(12):1266–77.CrossRef Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psych. 2011;168(12):1266–77.CrossRef
14.
go back to reference Honig LS, Mayeux R. Natural history of Alzheimer’s disease. Aging. 2001;13(3):171–82.PubMed Honig LS, Mayeux R. Natural history of Alzheimer’s disease. Aging. 2001;13(3):171–82.PubMed
15.
go back to reference Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Intern J Clin Pract. 2014;68(4):465–70.CrossRef Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Intern J Clin Pract. 2014;68(4):465–70.CrossRef
16.
go back to reference Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Therapeut. 2002;24(3):460–7.CrossRef Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Therapeut. 2002;24(3):460–7.CrossRef
17.
go back to reference Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918–29.PubMedCrossRef Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918–29.PubMedCrossRef
18.
go back to reference Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–30.PubMedCrossRef Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–30.PubMedCrossRef
19.
go back to reference Humbert IA, Fitzgerald ME, McLaren DG, Johnson S, Porcaro E, Kosmatka K, et al. Neurophysiology of swallowing: effects of age and bolus type. NeuroImage. 2009;44(3):982–91.PubMedCentralPubMedCrossRef Humbert IA, Fitzgerald ME, McLaren DG, Johnson S, Porcaro E, Kosmatka K, et al. Neurophysiology of swallowing: effects of age and bolus type. NeuroImage. 2009;44(3):982–91.PubMedCentralPubMedCrossRef
20.
go back to reference Humbert IA, McLaren DG, Malandraki G, Johnson SC, Robbins J. Swallowing intentional off-state in aging and Alzheimer’s disease: preliminary study. J Alzheimer’s Dis. 2011;26(2):347–54. Humbert IA, McLaren DG, Malandraki G, Johnson SC, Robbins J. Swallowing intentional off-state in aging and Alzheimer’s disease: preliminary study. J Alzheimer’s Dis. 2011;26(2):347–54.
22.
go back to reference Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013;56(1):1–9.PubMedCrossRef Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013;56(1):1–9.PubMedCrossRef
23.
go back to reference Morris H. Dysphagia in the elderly: a management challenge for nurses. Br J Nurs. 2006;15(10):558–62.PubMedCrossRef Morris H. Dysphagia in the elderly: a management challenge for nurses. Br J Nurs. 2006;15(10):558–62.PubMedCrossRef
25.
go back to reference Li I. Feeding tubes in patients with severe dementia. Am Fam Physician. 2002;65(8):1605–10.PubMed Li I. Feeding tubes in patients with severe dementia. Am Fam Physician. 2002;65(8):1605–10.PubMed
26.
go back to reference Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–65.PubMedCentralPubMedCrossRef Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–65.PubMedCentralPubMedCrossRef
27.
go back to reference Kalia M. Dysphagia and aspiration pneumonia in patients with Alzheimer’s disease. Metabolism. 2003;52(10 Suppl 2):36–8.PubMedCrossRef Kalia M. Dysphagia and aspiration pneumonia in patients with Alzheimer’s disease. Metabolism. 2003;52(10 Suppl 2):36–8.PubMedCrossRef
28.
29.
go back to reference James A. The legal and clinical implications of crushing tablet medication. Nurs Times. 2004;100(50):28–9.PubMed James A. The legal and clinical implications of crushing tablet medication. Nurs Times. 2004;100(50):28–9.PubMed
30.
go back to reference ARICEPT® (donepezil hydrochloride) tablets: Prescribing Information. Eisai, Inc.; 2013. ARICEPT® (donepezil hydrochloride) tablets: Prescribing Information. Eisai, Inc.; 2013.
31.
go back to reference NAMENDA XR® (memantine hydrochloride) extended release capsules: Prescribing Information. Forest Laboratories, Inc.; 2014. NAMENDA XR® (memantine hydrochloride) extended release capsules: Prescribing Information. Forest Laboratories, Inc.; 2014.
Metadata
Title
A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers
Authors
Ramesh Boinpally
Laishun Chen
Stephen R. Zukin
Natalie McClure
Robert K. Hofbauer
Antonia Periclou
Publication date
01-07-2015
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 7/2015
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-015-0296-4

Other articles of this Issue 7/2015

Clinical Drug Investigation 7/2015 Go to the issue